Business Description
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
ISIN : CNE100001R58
Share Class Description:
SZSE:300357: Class ACompare
Compare
Traded in other countries / regions
300357.China IPO Date
2014-01-21Description
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd is a Chinese bio-pharmaceutical company. It is engaged in the research development, production and sales of allergic diseases diagnosis and treatment products. The product portfolio of the company covers dust mites drops, dust mites skin prick diagnosis kit, silk, and others.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.9 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.21 | |||||
| Interest Coverage | 242.49 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 32.2 | |||||
| Beneish M-Score | -2.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.1 | |||||
| 3-Year EBITDA Growth Rate | 7.6 | |||||
| 3-Year EPS without NRI Growth Rate | 4.5 | |||||
| 3-Year FCF Growth Rate | -2.4 | |||||
| 3-Year Book Growth Rate | 14.5 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.18 | |||||
| 9-Day RSI | 52.74 | |||||
| 14-Day RSI | 49.17 | |||||
| 6-1 Month Momentum % | -10.98 | |||||
| 12-1 Month Momentum % | -44.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.85 | |||||
| Quick Ratio | 9.48 | |||||
| Cash Ratio | 7.92 | |||||
| Days Inventory | 495.63 | |||||
| Days Sales Outstanding | 72.38 | |||||
| Days Payable | 62.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.86 | |||||
| Dividend Payout Ratio | 0.33 | |||||
| 3-Year Dividend Growth Rate | 3.6 | |||||
| Forward Dividend Yield % | 0.86 | |||||
| 5-Year Yield-on-Cost % | 1.11 | |||||
| Shareholder Yield % | 0.6 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 95.35 | |||||
| Operating Margin % | 37.39 | |||||
| Net Margin % | 35.96 | |||||
| FCF Margin % | 18.5 | |||||
| ROE % | 14.85 | |||||
| ROA % | 12.78 | |||||
| ROIC % | 24.9 | |||||
| ROC (Joel Greenblatt) % | 47.31 | |||||
| ROCE % | 15.57 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 38.6 | |||||
| PE Ratio without NRI | 38.53 | |||||
| Shiller PE Ratio | 48.65 | |||||
| Price-to-Owner-Earnings | 58.61 | |||||
| PEG Ratio | 4.23 | |||||
| PS Ratio | 13.83 | |||||
| PB Ratio | 5.39 | |||||
| Price-to-Tangible-Book | 5.87 | |||||
| Price-to-Free-Cash-Flow | 74.54 | |||||
| Price-to-Operating-Cash-Flow | 35.57 | |||||
| EV-to-EBIT | 30.44 | |||||
| EV-to-EBITDA | 30.44 | |||||
| EV-to-Revenue | 12.45 | |||||
| EV-to-FCF | 67.32 | |||||
| Price-to-Projected-FCF | 3.07 | |||||
| Price-to-DCF (Earnings Based) | 1.59 | |||||
| Price-to-DCF (FCF Based) | 3.3 | |||||
| Price-to-Median-PS-Value | 0.52 | |||||
| Price-to-Peter-Lynch-Fair-Value | 5.68 | |||||
| Price-to-Graham-Number | 3.17 | |||||
| Price-to-Net-Current-Asset-Value | 9.85 | |||||
| Price-to-Net-Cash | 13.19 | |||||
| Earnings Yield (Greenblatt) % | 3.29 | |||||
| FCF Yield % | 1.33 | |||||
| Forward Rate of Return (Yacktman) % | 8.2 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 881.302 | ||
| EPS (TTM) (Â¥) | 0.605 | ||
| Beta | 1.45 | ||
| Volatility % | 46.93 | ||
| 14-Day RSI | 49.17 | ||
| 14-Day ATR (Â¥) | 0.940386 | ||
| 20-Day SMA (Â¥) | 22.933 | ||
| 12-1 Month Momentum % | -44.81 | ||
| 52-Week Range (Â¥) | 18.44 - 47.72 | ||
| Shares Outstanding (Mil) | 523.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Frequently Asked Questions
What is Zhejiang Wolwo Bio-Pharmaceutical Co Ltd(SZSE:300357)'s stock price today?
The current price of SZSE:300357 is ¥23.35. The 52 week high of SZSE:300357 is ¥47.72 and 52 week low is ¥18.44.
When is next earnings date of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd(SZSE:300357)?
The next earnings date of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd(SZSE:300357) is .
Does Zhejiang Wolwo Bio-Pharmaceutical Co Ltd(SZSE:300357) pay dividends? If so, how much?
The Dividend Yield %  of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd(SZSE:300357) is 0.86% (As of Today), Highest Dividend Payout Ratio of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd(SZSE:300357) was 0.45. The lowest was 0.23. And the median was 0.33. The  Forward Dividend Yield % of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd(SZSE:300357) is 0.86%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers